252 related articles for article (PubMed ID: 20732445)
1. The economics of priority review vouchers.
Dimitri N
Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
[TBL] [Abstract][Full Text] [Related]
2. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
Dimitri N
Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
[TBL] [Abstract][Full Text] [Related]
3. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
4. "Creating hope" and other incentives for drug development for children.
Connor E; Cure P
Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
[TBL] [Abstract][Full Text] [Related]
5. Preserving an Incentive for Global Health R&D: The Priority Review Voucher Secondary Market.
Robertson AS
Am J Law Med; 2016 May; 42(2-3):524-542. PubMed ID: 29086641
[TBL] [Abstract][Full Text] [Related]
6. The Commercial Market For Priority Review Vouchers.
Ridley DB; Régnier SA
Health Aff (Millwood); 2016 May; 35(5):776-83. PubMed ID: 27140982
[TBL] [Abstract][Full Text] [Related]
7. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
8. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
9. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
Ridley DB; Sánchez AC
Lancet; 2010 Sep; 376(9744):922-7. PubMed ID: 20833303
[TBL] [Abstract][Full Text] [Related]
10. US incentive scheme for neglected diseases: a good idea gone wrong?
Doshi P
BMJ; 2014 Jul; 349():g4665. PubMed ID: 25099712
[No Abstract] [Full Text] [Related]
11. Vouchers for FDA priority reviews.
Spatz ID
Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
[No Abstract] [Full Text] [Related]
12. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
13. In defence of priority review vouchers.
Sonderholm J
Bioethics; 2009 Sep; 23(7):413-20. PubMed ID: 19659848
[TBL] [Abstract][Full Text] [Related]
14. Orphan drugs of the future?
Service RF
Science; 2004 Mar; 303(5665):1798. PubMed ID: 15031491
[No Abstract] [Full Text] [Related]
15. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
16. Adoption agent.
Peota C
Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
[No Abstract] [Full Text] [Related]
17. FDA review vouchers.
Moe J; Grabowski H; Ridley D
N Engl J Med; 2009 Feb; 360(8):837; author reply 837-8. PubMed ID: 19228632
[No Abstract] [Full Text] [Related]
18. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
19. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
20. Priorities for the Priority Review Voucher.
Ridley DB
Am J Trop Med Hyg; 2017 Jan; 96(1):14-15. PubMed ID: 27573624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
